AVITHRAPID

AVITHRAPID

Biotechnology Research

Combating viral diseases with innovative therapeutic approaches.

About us

The European Consortium ""Antiviral Therapeutics for Rapid Response Against Pandemic Infectious Diseases"" (AVITHRAPID). The aim of the project is to establish a pipeline of small molecule-based antiviral agents that can be widely used and rapidly developed into therapies against emerging infectious diseases. As part of the project, the consortium intends to test a small molecule against Zika virus in a clinical trial. The European consortium "Antiviral Therapeutics for Rapid Response Against Pandemic Infectious Diseases" AVITHRAPID is part of the EU Horizon research programme call "Pandemic preparedness and response: Broad spectrum anti-viral therapeutics for infectious diseases with epidemic potential". The AVITHRAPID research consortium comprises 18 research institutions and companies from 8 countries, coordinated by the German Fraunhofer-Gesellschaft. AVITHRAPID started in January 2024 with a duration of 54 months .The Swiss Partners in the AVITHRAPID consortium are funded by the Swiss State Secretariat for Education, Research and Innovation SERI.

Website
www.avithrapid.eu
Industry
Biotechnology Research
Company size
51-200 employees
Type
Partnership
Founded
2024

Updates

Similar pages